4 citations
,
November 2020 in “Journal of Cosmetic Dermatology” This study found that Facebook hair loss treatment content is primarily advertisement-driven and seldom supported by medical evidence, with user engagement being generally low for evidence-based posts.
9 citations
,
April 2021 in “Expert opinion on pharmacotherapy” This review highlights that clascoterone, a newly FDA-approved topical androgen antagonist, effectively reduces both non-inflammatory and inflammatory acne lesions with no systemic effects, making it a promising new option for acne treatment in both male and female patients.
3 citations
,
December 2018 in “PubMed” This study provides an overview of popular over-the-counter hair loss products, highlighting limited evidence for non-approved treatments and suggesting the need for more rigorous studies.
1 citations
,
September 2022 in “Nepal journal of dermatology, venereology & leprology” This review examines the use of apremilast for non-FDA-approved dermatological conditions, noting varied efficacy but a favorable safety profile compared to conventional treatments.
July 2017 in “Nursing2023” Actemra is approved for a specific artery condition, HIV treatment adherence has improved, women may pay more for a hair loss product, and incorrect dosing of blood thinners can be risky.